- Home
- SNCR vs BCAB Comparison
SNCR vs BCAB Comparison
Compare SNCR & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCR
- BCAB
- Stock Information
- Founded
- SNCR 2000
- BCAB 2007
- Country
- SNCR United States
- BCAB United States
- Employees
- SNCR N/A
- BCAB N/A
- Industry
- SNCR EDP Services
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- SNCR Technology
- BCAB Health Care
- Exchange
- SNCR Nasdaq
- BCAB Nasdaq
- Market Cap
- SNCR 137.5M
- BCAB 96.2M
- IPO Year
- SNCR 2006
- BCAB 2020
- Fundamental
- Price
- SNCR $11.25
- BCAB $2.08
- Analyst Decision
- SNCR
- BCAB Strong Buy
- Analyst Count
- SNCR 0
- BCAB 2
- Target Price
- SNCR N/A
- BCAB $6.00
- AVG Volume (30 Days)
- SNCR 81.2K
- BCAB 1.6M
- Earning Date
- SNCR 11-12-2024
- BCAB 11-08-2024
- Dividend Yield
- SNCR N/A
- BCAB N/A
- EPS Growth
- SNCR N/A
- BCAB N/A
- EPS
- SNCR N/A
- BCAB N/A
- Revenue
- SNCR $167,615,000.00
- BCAB N/A
- Revenue This Year
- SNCR $7.76
- BCAB N/A
- Revenue Next Year
- SNCR $5.83
- BCAB N/A
- P/E Ratio
- SNCR N/A
- BCAB N/A
- Revenue Growth
- SNCR 33.39
- BCAB N/A
- 52 Week Low
- SNCR $2.70
- BCAB $1.14
- 52 Week High
- SNCR $15.46
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- SNCR 43.11
- BCAB 55.80
- Support Level
- SNCR $10.45
- BCAB $1.87
- Resistance Level
- SNCR $11.44
- BCAB $2.13
- Average True Range (ATR)
- SNCR 0.57
- BCAB 0.12
- MACD
- SNCR -0.06
- BCAB 0.00
- Stochastic Oscillator
- SNCR 31.58
- BCAB 68.90
About SNCR Synchronoss Technologies Inc.
Synchronoss Technologies Inc is a leading provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and highly scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.